Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
The purpose of this phase II trial is to evaluate the safety and efficacy of standard of care chemotherapy followed by stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FKA inhibitor Defactinib (experimental arm) or standard of care therapy followed by SBRT (control arm) in patients with advanced pancreatic cancer.
Study ID: 202106061
Trial Phase: Phase II
Trial Sponsor: Washington University School of Medicine
Therapies Used in This Trial: Defactinib